# A Study to Investigate Alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid (AMPA Gamma 8) Receptor Occupancy of JNJ-64140284 With Newly Developed Transmembrane AMPA Receptor Regulatory Protein (TARP)-Gamma 8 Positron Emission Tomography (PET) [18F]JNJ-64511070 in Healthy Men

> **NCT03693391** · PHASE1 · TERMINATED · sponsor: **Janssen Research & Development, LLC** · enrollment: 22 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** JNJ-64140284
- **DRUG:** Fluorine-18 Labeled [18F]-JNJ-64511070

## Key facts

- **NCT ID:** NCT03693391
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-10-17
- **Primary completion:** 2019-03-02
- **Final completion:** 2019-03-13
- **Target enrollment:** 22 (ACTUAL)
- **Why stopped:** stopped because of a business decision
- **Last updated:** 2025-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03693391

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03693391, "A Study to Investigate Alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid (AMPA Gamma 8) Receptor Occupancy of JNJ-64140284 With Newly Developed Transmembrane AMPA Receptor Regulatory Protein (TARP)-Gamma 8 Positron Emission Tomography (PET) [18F]JNJ-64511070 in Healthy Men". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT03693391. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*